Insights into the Window of Opportunity and Outcome Measures in Patients with Moderate to Severe Hidradenitis Suppurativa Treated with Secukinumab: A Real-World Study.

Dermatol Ther (Heidelb) · 2024 · PMC11264522 · PMID 38896382

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Similarly, combination therapy did not increase response probability and actually showed a trend towards worse HiSCR and IHS4-55 response rates.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.